Literature DB >> 14675268

Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.

Kyoichi Adachi1, Tomoyuki Hashimoto, Naoharu Hamamoto, Kazuya Hirakawa, Masatoshi Niigaki, Tatsuya Miyake, Hiroyuki Taniura, Masahiro Ono, Takekazu Kaji, Hiroshi Suetsugu, Junko Yagi, Yoshinori Komazawa, Takafumi Mihara, Tomoko Katsube, Hirofumi Fujishiro, Toshihiro Shizuku, Shuzo Hattori, Shun Yamamoto, Yoshikazu Kinoshita.   

Abstract

BACKGROUND AND AIM: Rabeprazole has a faster onset of antisecretory activity than omeprazole and lansoprazole. The aim of the present study was to clarify whether there is any difference in the speed of symptom relief in patients with reflux esophagitis following the administration of these three proton pump inhibitors (PPI).
METHODS: Eighty-five patients with erosive reflux esophagitis were randomized to receive 8 weeks of 20 mg of omeprazole (n = 30), 30 mg of lansoprazole (n = 25), or 20 mg of rabeprazole (n = 30) once a morning. Daily changes in heartburn and acid reflux symptoms in the first 7 days of administration were assessed using a six-point scale (0: none, 1: mild, 2: mild-moderate, 3: moderate, 4: moderate-severe, 5: severe).
RESULTS: The mean heartburn score in patients administered rabeprazole decreased more rapidly than those given the other PPI. Complete heartburn remission also occurred more rapidly in patients administered rabeprazole (compared with omeprazole: P = 0.035, compared with lansoprazole: P = 0.038 by log-rank test). No differences were seen in the rate of endoscopic healing of reflux esophagitis at 8 weeks between the three treatment regimens.
CONCLUSION: Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675268     DOI: 10.1046/j.1440-1746.2003.03190.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.

Authors:  Kiyoshi Ashida; Yoshikazu Kinoshita; Michio Hongo
Journal:  Dig Dis Sci       Date:  2011-02-08       Impact factor: 3.199

2.  Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease.

Authors:  Yoon Se Lee; Seung-Ho Choi; Young Ik Son; Young-Hak Park; Sang Yoon Kim; Soon Yuhl Nam
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-11       Impact factor: 2.503

3.  Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.

Authors:  Kayoko Oda; Ryuichi Iwakiri; Megumi Hara; Kazuyo Watanabe; Akiko Danjo; Ryo Shimoda; Atsushi Kikkawa; Akifumi Ootani; Hiroyuki Sakata; Seiji Tsunada; Kazuma Fujimoto
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

4.  Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.

Authors:  Mitsushige Sugimoto; Masafumi Nishino; Chise Kodaira; Mihoko Yamade; Takahiro Uotani; Mutsuhiro Ikuma; Kazuo Umemura; Takahisa Furuta
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

5.  It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients.

Authors:  Motoyasu Kusano; Naohito Shirai; Kanako Yamaguchi; Michio Hongo; Tsutomu Chiba; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

6.  Acid and non-acid reflux patterns in patients with erosive esophagitis and non-erosive reflux disease (NERD): a study using intraluminal impedance monitoring.

Authors:  José M Conchillo; Matthijs P Schwartz; Mohamed Selimah; Melvin Samsom; Daniel Sifrim; André J Smout
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

7.  The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease.

Authors:  Ying Chen; Feng Wang; Yuanxi Jiang; Chen Wang; Liwen Yao; Ping Wu; Yili Tong; Huihui Sun; Shuchang Xu
Journal:  Gastroenterol Res Pract       Date:  2013-02-28       Impact factor: 2.260

8.  A review of rabeprazole in the treatment of acid-related diseases.

Authors:  Fabio Pace; Stefano Pallotta; Stefania Casalini; Gabriele Bianchi Porro
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 9.  Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis.

Authors:  X M Xia; H Wang
Journal:  Gastroenterol Res Pract       Date:  2013-09-09       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.